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The lymphatic system plays an important role in the induction of the immune response by 
transporting antigens, inflammatory mediators, and leukocytes from peripheral tissues to 
draining lymph nodes. It is emerging that lymphatic endothelial cells (LECs) are playing 
an active role in this context via the expression of chemokines, inflammatory mediators 
promoting cell migration, and chemokine receptors. Particularly, LECs express atypical 
chemokine receptors (ACKRs), which are unable to promote conventional signaling and 
cell migration while they are involved in the regulation of chemokine availability. Here, we 
provide a summary of the data on the role of ACKR2 expressed by lymphatics, indicating 
an essential role for this ACKRs in the regulation of the inflammation and the immune 
response in different pathological conditions, including infection, allergy, and cancer.
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inTRODUCTiOn
Chemokines and Chemokine Receptors
Chemokines are small chemotactic cytokines secreted by different cell types (e.g., immune cells, 
cancer cells, and endothelial cells) mainly involved in the regulation of immune cell migration dur-
ing routine immune surveillance, inflammation, and development (1). According to the position of 
conserved cysteine residues in their N-terminus, chemokines are classified into four subfamilies: 
CXC, CX3C, CC, and C (2). In addition, they can be classified, on the basis of the conditions dur-
ing which they are produced, in homeostatic or inflammatory chemokines (3, 4). Homeostatic 
chemokines (e.g., CCL19, CCL20, and CCL21) are constitutively produced and regulate leukocytes 
migration in basal conditions. Inflammatory chemokines (e.g., CXCL8, CCL2, and CCL3) are pro-
duced under pathological conditions, and they can act as secondary mediators induced by primary 
pro-inflammatory factors, such as IL-1 and TNF-α. Inflammatory chemokines actively participate 
in the inflammatory response attracting immune cells to the site of injury. Beyond their unequivocal 
role in regulating leukocyte recruitment, other activities, such as regulation of angiogenesis, fibrosis, 
proliferation, homeostasis, and cancer cell dissemination, have been attributed to chemokines (5–8).
The specific effects of chemokines on their target cells are mediated by chemokine receptors, 
members of a family of 7-transmembrane G-protein-coupled receptors (1). Chemokine receptors 
have a highly conserved structure, consisting of a single polypeptide chain with three intracellular 
and extracellular loops, an external N-terminus domain essential for the specificity of ligand 
binding, and an intracellular carboxy-terminus that, in concert with other motifs, such as the 
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Asp–Arg–Tyr–Leu–Ala–Ile–Val (DRYLAIV) motif between 
the third transmembrane domain and the second intracel-
lular loop, is involved in receptor signaling. As a general rule, 
chemokine binding to the receptor causes conformational 
changes that trigger intracellular signaling pathways involved 
in cell activation and migration toward increasing chemokine 
gradients (9). Depending on the type of chemokine they bind, 
chemokine receptors can be classified as CXCR, CCR, CX3CR, 
or XCR1.
Beyond canonical chemokine receptors, a smaller family of 
atypical chemokine receptors (ACKRs) has been identified (10). 
These receptors are called atypical because they share structural 
features with canonical chemokine receptors and bind ligands 
with high affinity, yet, they are not able to induce cell migra-
tion. Indeed, these receptors have an altered DRYLAIV motif 
and, differently from the canonical chemokine receptors, upon 
chemokine engagement, they do not induce any GPCR signal-
ing. Rather, ACKRs internalize and transport chemokines to the 
degradative compartment, modulating chemokine concentration 
and bioavailability. The family of ACKRs includes four receptors 
named according to the new nomenclature: ACKR1 (previously 
called DARC), ACKR2 (D6), ACKR3 (CXCR7), and ACKR4 
(CCX-CKR) (11).
Role of Chemokine and Chemokine 
Receptor expression in Lymphatic 
Function
Chemokine and chemokine receptors expressed by lymphatic 
vessels (LVs) have been mainly studied in the context of leukocyte 
traffic. Indeed, the lymphatic system represents an important 
transport network for leukocytes, in particular antigen-presenting 
cells that migrate, through afferent LVs, from the periphery to the 
lymph nodes (LNs). This trafficking is mainly dictated by CCL21. 
CCL21 is constitutively expressed by LEC and can be upregu-
lated by inflammatory stimuli, such as TNF-α, which induce the 
release of CCL21 intracellular stores (12). CCL21 promotes the 
recruitment of CCR7-positive dendritic cells (DCs) but also of 
neutrophils and T cells to draining LNs (13–15).
Interestingly, lymphatics produce many other chemokines in 
a stimulus-specific manner, indicating that they can fine-tune 
leukocyte recruitment (16). CXCL12 and CX3CL1 were found to 
induce DC migration to LNs (17, 18) while the function of other 
inflammatory chemokines produced by inflamed LEC, such as 
CCL2 and CXCL8, is not fully understood (12, 19).
Besides, in keeping with chemokine receptor expression 
on cancer cells, leukocyte-like homing toward LVs and LNs 
plays an important role in promoting cancer cell migration and 
metastasis. For example, CCR7-positive cancer cells metastasize 
to LNs where CCL19 and CCL21, the ligands for CCR7, are 
produced (20).
In addition to producing chemokines, lymphatic endothelial 
cells (LECs) express canonical chemokine receptors. Primary 
culture of murine LEC was found to be positive for the expres-
sion of CCR5, CCR9, CXCR4, and CXCR6, whereas they weakly 
expressed CCR4, CCR6, CCR8, CCR10, CXCR3, and CX3CR1 
(21). The function of these receptors expressed by LEC is still 
unknown, with the exception of CXCR4 that has a role in promot-
ing lymphangiogenesis, similar to its angiogenic role in vascular 
endothelial cells (21).
Interestingly, LECs express ACKRs: ACKR1 is expressed 
by human podoplanin low LECs (22); ACKR2 by many 
human tissues on afferent lymphatic (23); ACKR3 by human 
LECs, with restricted expression in the tonsil and kidney and 
increased expression during renal allograft rejection (24); and 
finally, ACKR4 is expressed by LEC in the LN capsule (25, 26). 
Here, we are summarizing data on the expression and role of 
ACKR2 by LECs. Increasing evidence suggests a crucial role 
for this receptor in the regulation of inflammation and immune 
response (12, 27).
ACKR2/D6
The atypical chemokine receptor ACKR2, also known as D6 or 
CCBP2, is a highly promiscuous receptor capable of binding 
the majority of inflammatory CC-chemokines (28). Initially, 
according to its “atypical” features, it was assumed that ACKR2 
was a non-signaling chemokine receptor. However, it was later 
demonstrated that not only is ACKR2 capable of internalization 
and scavenging of its ligands but that it also activates a β-arrestin-
dependent signaling pathway, promoting receptor internalization 
and recycling to the cell membrane (29, 30).
ACKR2 expression by Lymphatics
ACKR2 is expressed by trophoblasts in the placenta, by some 
leukocytes (31), and by LECs. Indeed, Nibbs et al., in a seminal 
paper (23), demonstrated that within non-inflamed tissues, 
human LECs, but not vascular endothelial cells, express ACKR2. 
Moreover, they found that the receptor was expressed on a subset 
of lymphatics, thus suggesting the existence of functional het-
erogeneity within the lymphatic vasculature. Specifically, ACKR2 
expression was found in human skin sections only in afferent 
LVs, both in regions near the epidermis but also deeper within 
the dermis. ACKR2 was found in small lymphatics in the villi 
of small and large intestine and in the lamina propria mucosae 
of colon and large collective lymphatics located in the muscular 
layer. The appendix also showed ACKR2-positive lymphatics in 
lymphoid tissue of lamina propria and in the lamina muscolaris 
externa. ACKR2 was also detected in other secondary lymphoid 
organs such as tonsils, spleen, and LNs on sinus-like channels 
and vessels in the parafollicular areas of the tonsils and the red 
pulp of the spleen. ACKR2 was not detected in heart, kidney, 
liver, skeletal muscle, brain, cerebellum, pancreas, prostate, and 
thyroid, whereas it was found in liver, lung, and placenta, but not 
on LECs (23).
The regulation of ACKR2 expression in LECs was only stud-
ied in vitro using human dermal LECs. McKimmie et al. found 
that ACKR2 is upregulated by the lymphangiogenic cytokine 
vascular endothelial growth factor-D, by the immunosuppressive 
cytokine transforming growth factor-β, and by the inflammatory 
mediators IL-6, type-I IFNs, and IFN-γ. On the contrary, the pro-
inflammatory cytokine IL-1α induced a significant downregula-
tion of ACKR2 (32).
FiGURe 1 | Role of ACKR2 expression on lymphatic vessels. ACKR2 expression on lymphatic endothelial cells, by scavenging inflammatory CC chemokines, 
shapes functional gradients promoting appropriate leukocyte recruitment into inflamed tissues, regulates their trafficking into lymph nodes, and controls lymphatic 
vessel density.
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The Function of ACKR2  
expressed by LeCs
Extensive evidence indicates that ACKR2 is involved in the regu-
lation of chemokine levels around afferent LVs and in the removal 
of chemokines from inflamed tissues, thus acting as scavenger 
and “gatekeeper” by limiting the access, the interaction, and the 
inappropriate accumulation of inflammatory leukocytes in the 
lymphatic system, in particular in the subcapsular sinus region 
of LNs (33, 34).
McKimmie et al. observed a variable expression of ACKR2 
on individual cutaneous LVs and a biased distribution toward 
the luminal face of the LECs, thus suggesting an involvement 
of ACKR2 in suppressing inflammatory leukocyte binding to 
lymphatic endothelial surfaces (32). Specifically, they dem-
onstrated that ACKR2 contributes to the efficiency of antigen 
presentation of DCs, which is crucial in maintaining immune 
surveillance. Indeed, ACKR2, by scavenging pro-inflammatory 
chemokines, suppresses inflammatory chemokine binding to 
the LEC surface, thus increasing the availability and contribut-
ing to selective presentation of CCR7 ligands that attract CCR7+ 
mature DCs (32).
Recently, it was found that ACKR2 regulates LV density, 
competing with the canonical chemokine receptor CCR2 for 
the binding of CCL2, a chemokine produced in the skin during 
inflammation that drains into the LNs where it induces mono-
cyte infiltration (Figure 1). By immunostaining of LV networks, 
Lee  et  al. found that Ackr2−/− mice displayed an increased LV 
density in the ears, diaphragms, and popliteal LNs in resting 
and regenerative conditions, compared to WT mice. Further 
investigation on E15.5 embryonic mice showed the presence of 
macrophages in proximity of developing LVs and involved in 
developmental lymphangiogenic processes. These macrophages, 
recruited by CCL2 and phenotyped as CD11bhigh F4/80low Lyve-
1+, were significantly higher in Ackr2−/− mice whereas they were 
reduced in Ccr2−/− mice. Together, this evidence demonstrated 
that ACKR2 and CCR2 reciprocally regulate macrophage prox-
imity to LVs and contribute to control lymphangiogenesis in 
inflammatory conditions. Accordingly, Ackr2−/− mice displayed 
relatively inefficient antigen presentation (35).
inSiGHTS inTO LYMPHATiC ACKR2 
eXPReSSiOn AnD FUnCTiOn DURinG 
DiSeASe
Several studies using ACKR2-deficient mice or human samples 
have demonstrated an important role of ACKR2 expressed 
by LVs in inflammatory conditions and in cancer. The general 
emerging picture is that ACKR2 acts as a negative regulator of 
inflammation, but contrasting results were published on its role 
in the control of adaptive immune responses and in autoimmune 
disease development.
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The Role of Lymphatic ACKR2  
expression in inflammation
Using murine models of cutaneous inflammation, such as phor-
bol ester skin painting and subcutaneous injection of complete 
Freund’s adjuvant, it was demonstrated that Ackr2−/− mice 
develop an exacerbated inflammatory response with increased 
necrotic areas, angiogenesis, and a significantly higher leukocyte 
infiltration compared to WT mice (36–38). In both models, 
ACKR2 promoted the resolution of cutaneous inflammation by 
chemokine clearance.
The cutaneous lesions developing in ACKR2-deficient mice 
after phorbol ester skin painting resemble human psoriasiform 
pathology, indicating a possible role of ACKR2 in the control 
of this pathology (36). Using a psoriasis-like skin inflammation 
model induced by imiquimod, it has been shown that localized 
inflammation and IFN-γ induce the upregulation of ACKR2 in 
remote tissues that control the spread of psoriasiform inflam-
mation inhibiting T cell epidermal influx (39). Similar results 
were found in psoriatic patient lesions in which ACKR2 is highly 
expressed in the surrounding skin in comparison with healthy 
controls, while it is downregulated in lesional and perilesional 
sites (36, 37, 40).
Several papers have also described an important role for 
ACKR2 expressed by lung LVs in the regulation of pulmonary 
inflammation. ACKR2 expression is upregulated in the LVs and 
in alveolar macrophages in the lung of patients with chronic 
obstructive pulmonary disease. In this context, the increased 
expression of ACKR2 could regulate the trafficking of leuko-
cytes from the lungs to draining LNs (41, 42). ACKR2 was also 
found on LECs in lungs and LNs from patients with pulmonary 
tuberculosis (43). Ackr2−/− mice infected by Mycobacterium 
tuberculosis show reduced survival, compared to WT mice, due 
to an increased number of lung and LN-infiltrating mononu-
clear cells and an abnormal production of pro-inflammatory 
cytokines and CC chemokines (43). Interestingly, inhibition 
of inflammatory chemokines in Ackr2−/− mice led to less 
controlled growth of M. tuberculosis, indicating that ACKR2 
has an important role also in immune activation. The role of 
ACKR2 in the lung was also studied in an allergen-induced 
airway disease model. Allergen-challenged ACKR2-deficient 
mice had more lung inflammation compared to WT counter-
parts, having more DCs, T cells, and eosinophils in the lung 
parenchyma and more eosinophils in airways. Surprisingly, 
ACKR2-deficient mice had reduced airway responses to 
methacholine compared to WT mice, indicating that ACKR2 
has opposing effects on allergic inflammation and airway 
reactivity (44).
Contrasting results have been published on the role of ACKR2 
expressed by LVs in intestinal inflammation. ACKR2 is overex-
pressed by LVs in the gut in inflammatory bowel disease, and it 
was found to have a protective role in a dextran sulfate sodium 
(DSS)-induced colitis mouse model (45). Indeed, Ackr2−/− mice 
have increased levels of inflammatory chemokines and infiltrat-
ing leukocytes, and increased intestinal inflammation, weight 
loss, and disease activity index, compared to WT mice (45). On 
the contrary, using the same murine model of intestinal inflam-
mation, reduced clinical symptoms and tissue pathology in 
response to DSS in ACKR2 deficient were observed compared to 
WT mice. This protection is due to increased secretion of IL-17A 
by γδ-T cells in the lamina propria (46).
The role of ACKR2 in autoimmune diseases is also debated. 
ACKR2-deficient mice were described to be protected from 
the development of an experimental model of autoimmune 
encephalomyelitis (EAE) due to impaired migration of DCs 
and inhibition of T cell priming (47). More recently, using the 
same EAE model, it was described that ACKR2-deficient mice 
are not protected from the development of the disease but, on 
the contrary, they develop worse clinical symptoms compared to 
WT mice due to increased innate B cell-dependent production 
of IL-17 (48). Finally, in a murine model of graft versus host 
disease, we have found that ACKR2-deficient mice are protected 
from the development of the disease due to increased number 
of inflammatory monocytes with enhanced immunosuppressive 
activity (49).
In conclusion, ACKR2 expressed by LVs has an anti- 
inflammatory function by clearing chemokines present in 
inflamed tissues. This activity promotes the migration of DC 
to LN through LVs that is necessary for the induction of the 
adaptive response but that can be detrimental in autoimmune 
diseases. Conflicting phenotypes published could possibly be 
explained by the fact that ACKR2 is also controlling IL-17 pro-
duction, a critical cytokine for inflammatory and autoimmune 
diseases.
The Role of Lv ACKR2 in Cancer  
and Metastasis
In human cancer lesions, ACKR2 was found to be expressed by 
peritumoral LVs in oral squamous cell carcinomas and in colon 
cancer. Accordingly, murine models of inflammation-induced 
cancer in the skin and in the gut revealed that ACKR2 protects 
mice from the development of tumors by dampening inflamma-
tion (38, 45).
ACKR2 was found to be protective in cancer progression 
also when expressed by tumor cells, by inhibiting inflammatory 
chemokines and protumoral leukocyte infiltration. ACKR2 is 
expressed by vascular tumors with lymphatic origin or differen-
tiation (23) and is highly expressed by Kaposi’s sarcoma spindle 
cells (32, 50–52). In this latter tumor, we have found that ACKR2 
expression is downregulated in more aggressive tumors by the 
activation of the KRAS/BRAF/ERK pathway, thus unleashing 
chemokine-mediated macrophage recruitment and their acqui-
sition of an M2-like phenotype that sustains angiogenesis and 
tumor growth (52, 53).
ACKR2 was also found to be expressed in human breast 
cancer, and its expression predicts relapse-free survival (RFS) 
(54) while it is inversely correlated with axillary lymph node 
metastasis (55). Of note, a functional non-synonymous single 
nucleotide polymorphism of ACKR2 is associated with lymph 
node metastasis and RFS in breast cancer, indicating that the 
expression and function of ACKR2 in the host could also affect 
tumor progression (54, 56).
In conclusion, while it is clear that in inflammation-induced 
cancer ACKR2 expression by tumor cells inhibits cancer progres-
sion by decreasing macrophage infiltration and angiogenesis, 
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further studies are necessary to understand the exact nature of 
the role of ACKR2 expressed by the host and how it can affect 
tumor progression and metastasis.
COnCLUDinG ReMARKS
Lymphatic vessels have been traditionally considered as an inert 
drainage system, which passively transports fluids, proteins, 
and leukocytes. However, an increasing number of studies show 
that lymphatics play a much more active role, especially in the 
context of inflammation and ongoing immune responses. The 
expression of chemokine and chemokine receptors by LECs can 
be seen as evidence in support of an active role for lymphatics in 
regulating immunity. By the expression of ACKRs, LECs create 
and shape functional gradients of chemokines and modulate 
leukocyte recruitment. Moreover, they avoid inappropriate 
accumulation of chemokines and immune cells into inflamed 
tissues.
Here, we reported data demonstrating the essential role of 
ACKR2, expressed by LECs, in regulating chemokine concen-
tration and leukocyte migration. This promotes the resolution 
of inflammatory responses in different pathological conditions 
including infection, allergy, and cancer. This evidence enables 
the speculation that ACKR2 could be considered as a potential 
therapeutic target to be induced in order to attenuate inflamma-
tion, e.g., during psoriasis and lung infection.
Even if the role of ACKR2 in inflammatory conditions has 
been clarified, further experimental studies are required to bet-
ter understand its role in tumors. In this context, although an 
inverse correlation between ACKR2 expression and tumor stage 
was observed, it is unclear whether this correlation can be utilized 
as a clinical prognostic marker. Another challenging issue yet to 
be resolved is to understand whether ACKR2 could be a putative 
target for cancer immunotherapy. Indeed, it remains to be investi-
gated if the activity of ACKR2 on lymphatics promotes or inhibits 
adaptive immune responses and whether ACKR2, by shaping 
chemokine gradients, can influence cancer cell dissemination to 
metastatic organs.
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